New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events Seite 1
02.10.2022 - Data presented at the Heart Failure Society of America annual scientific meetingNew analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart ... Seite 1
Source: wallstreet-online.de